

Douglas L Jennings

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/265026/publications.pdf>

Version: 2024-02-01

50
papers

790
citations

516710

16
h-index

552781

26
g-index

50
all docs

50
docs citations

50
times ranked

904
citing authors

#	ARTICLE	IF	CITATIONS
1	PCSK9 inhibitors safely and effectively lower LDL after heart transplantation: a systematic review and meta-analysis. <i>Heart Failure Reviews</i> , 2023, 28, 149-156.	3.9	3
2	Angiotensin receptor neprilysin inhibitor use in patients with left ventricular assist devices: A single-center experience. <i>International Journal of Artificial Organs</i> , 2022, 45, 118-120.	1.4	2
3	Nitazoxanide treatment for norovirus infection in solid organ transplant recipients. <i>Clinical Transplantation</i> , 2022, 36, e14594.	1.6	11
4	Nirmatrelvir/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants. <i>American Journal of Transplantation</i> , 2022, 22, 1925-1926.	4.7	54
5	Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2022, 22, 2083-2088.	4.7	64
6	COVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era. <i>American Journal of Transplantation</i> , 2022, 22, 2682-2688.	4.7	35
7	Methylene Blue Does Not Improve Vasoplegia After Left Ventricular Assist Device Implantation. <i>Annals of Thoracic Surgery</i> , 2021, 111, 800-808.	1.3	6
8	Pharmacotherapy for durable left ventricular assist devices. <i>Pharmacotherapy</i> , 2021, 41, 14-27.	2.6	6
9	Immunosuppression considerations in simultaneous organ transplant. <i>Pharmacotherapy</i> , 2021, 41, 59-76.	2.6	7
10	SARS-CoV-2 infection increases tacrolimus concentrations in solid organ transplant recipients. <i>Clinical Transplantation</i> , 2021, 35, e14193.	1.6	14
11	A reappraisal of the pharmacologic management of gastrointestinal bleeding in patients with continuous flow left ventricular assist devices. <i>Heart Failure Reviews</i> , 2021, 26, 277-288.	3.9	5
12	Pre-transplant amiodarone use does not affect long-term heart transplant survival. <i>Pharmacotherapy</i> , 2021, , .	2.6	1
13	Impact of heart failure drug therapy on rates of gastrointestinal bleeding in LVAD recipients: An INTERMACS analysis. <i>International Journal of Artificial Organs</i> , 2021, 44, 965-971.	1.4	8
14	Less bleeding associated with apixaban versus other direct acting oral anticoagulation in solid organ transplant recipients. <i>Clinical Transplantation</i> , 2021, 35, .	1.6	6
15	Clinical outcomes of older adults listed for heart transplantation in the <sc>United States</sc>. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 2507-2517.	2.6	12
16	Optimizing anticoagulation for patients receiving Impella support. <i>Pharmacotherapy</i> , 2021, 41, 932-942.	2.6	22
17	Chronic intermittent intravenous immunoglobulin in heart transplant recipients with elevated donor-specific antibody levels. <i>Clinical Transplantation</i> , 2021, , e14524.	1.6	1
18	Use of cangrelor during venoarterial extracorporeal membrane oxygenation following percutaneous coronary intervention. <i>Artificial Organs</i> , 2020, 44, 339-340.	1.9	7

#	ARTICLE	IF	CITATIONS
19	Discontinuing amiodarone treatment prior to heart transplantation lowers incidence of severe primary graft dysfunction. <i>Clinical Transplantation</i> , 2020, 34, e13779.	1.6	9
20	PCSK9 Inhibitor Use in Heart Transplant Recipients: A Case Series and Review of the Literature. <i>Transplantation</i> , 2020, 104, e38-e39.	1.0	9
21	Gut microbial diversity, inflammation, and oxidative stress are associated with tacrolimus dosing requirements early after heart transplantation. <i>PLoS ONE</i> , 2020, 15, e0233646.	2.5	15
22	Desensitizing highly sensitized heart transplant candidates with the combination of belatacept and proteasome inhibition. <i>American Journal of Transplantation</i> , 2020, 20, 3620-3630.	4.7	27
23	Red Cell Distribution Width Predicts 90 Day Mortality in Continuous-Flow Left Ventricular Assist Device Patients. <i>ASAIO Journal</i> , 2019, 65, 233-240.	1.6	4
24	Prior Amiodarone Exposure Reduces Tacrolimus Dosing Requirements in Heart Transplant Recipients. <i>Progress in Transplantation</i> , 2019, 29, 129-134.	0.7	4
25	Management of primary graft failure after heart transplantation: Preoperative risks, perioperative events, and postoperative decisions. <i>Clinical Transplantation</i> , 2019, 33, e13557.	1.6	13
26	Survey of Anticoagulation Practices with the Impella Percutaneous Ventricular Assist Device at High-Volume Centers. <i>Journal of Interventional Cardiology</i> , 2019, 2019, 1-6.	1.2	30
27	Engineering a Brighter Future: The Evolving Role of the Pharmacist in the Era of the HeartMate 3. <i>Annals of Pharmacotherapy</i> , 2019, 53, 430-433.	1.9	0
28	Outcomes associated with mammalian target of rapamycin (mTOR) inhibitors in heart transplant recipients: A meta-analysis. <i>International Journal of Cardiology</i> , 2018, 265, 71-76.	1.7	32
29	Meta-analysis of Time in Therapeutic Range in Continuous-flow Left Ventricular Assist Device Patients Receiving Warfarin. <i>Artificial Organs</i> , 2018, 42, 700-704.	1.9	29
30	Reply. <i>Annals of Thoracic Surgery</i> , 2018, 106, 309-310.	1.3	0
31	Abciximab/Heparin Therapy for Left Ventricular Assist Device Implantation in Patients With Heparin-Induced Thrombocytopenia. <i>Annals of Thoracic Surgery</i> , 2018, 105, 122-128.	1.3	6
32	Increase in short-term of rejection in heart transplant patients receiving granulocyte colony-stimulating factor. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 1475.	0.6	1
33	Mammalian Target of Rapamycin Inhibitors and Survival in Heart Transplant Recipients. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2859-2860.	2.8	0
34	Pre-cardiac transplant amiodarone use is not associated with postoperative mortality: An updated meta-analysis. <i>International Journal of Cardiology</i> , 2017, 236, 345-347.	1.7	11
35	Inhaled Pulmonary Vasodilator Therapy for Management of Right Ventricular Dysfunction after Left Ventricular Assist Device Placement and Cardiac Transplantation. <i>Pharmacotherapy</i> , 2017, 37, 944-955.	2.6	35
36	Pharmacotherapeutic Management of Gastrointestinal Bleeding in Patients with Continuous-flow Left Ventricular Assist Devices. <i>Pharmacotherapy</i> , 2017, 37, 1432-1448.	2.6	29

#	ARTICLE	IF	CITATIONS
37	Dose-dependent association between amiodarone and severe primary graft dysfunction in orthotopic heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 1226-1233.	0.6	42
38	Pharmacologic Considerations in the Management of Patients Receiving Left Ventricular Percutaneous Mechanical Circulatory Support. <i>Pharmacotherapy</i> , 2017, 37, 1272-1283.	2.6	26
39	A multidisciplinary team-based process improves outpatient anticoagulation quality with continuous-flow left-ventricular assist devices. <i>International Journal of Cardiology</i> , 2016, 218, 118-119.	1.7	14
40	Pre-Cardiac Transplant Amiodarone Use Increases Postoperative Mortality. <i>Annals of Pharmacotherapy</i> , 2016, 50, 514-515.	1.9	4
41	Relationship of hemolysis with discordance in paired activated partial thromboplastin time and anti-Factor Xa measurements in continuous-flow left ventricular assist device patients. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 1365-1367.	0.6	2
42	Device-Related Thrombosis in Continuous-Flow Left Ventricular Assist Device Support. <i>Journal of Pharmacy Practice</i> , 2016, 29, 58-66.	1.0	12
43	Impact of Platelet Functional Assays on the Cost of Treating Suspected Heparin-Induced Thrombocytopenia. <i>Journal of Pharmacy Practice</i> , 2015, 28, 398-403.	1.0	3
44	Impact of pre-implant amiodarone exposure on outcomes in cardiac transplant recipients. <i>Heart Failure Reviews</i> , 2015, 20, 573-578.	3.9	14
45	Dosing of Vancomycin in Patients with Continuous-Flow Left Ventricular Assist Devices: A Clinical Pharmacokinetic Analysis. <i>International Journal of Artificial Organs</i> , 2014, 37, 270-274.	1.4	7
46	Clinical Outcomes with Beta-blockers after Myocardial Infarction: Finding the Right Patient and the Right Regimen. <i>American Journal of Medicine</i> , 2014, 127, e17.	1.5	0
47	Safety of Anticoagulation Reversal in Patients Supported with Continuous-Flow Left Ventricular Assist Devices. <i>ASAIO Journal</i> , 2014, 60, 381-384.	1.6	18
48	Clinical Outcomes Associated With Chronic Antimicrobial Suppression Therapy in Patients With Continuous-Flow Left Ventricular Assist Devices. <i>Artificial Organs</i> , 2014, 38, 875-879.	1.9	41
49	Effective Anticoagulation for a Percutaneous Ventricular Assist Device Using a Heparin-Based Purge Solution. <i>Annals of Pharmacotherapy</i> , 2013, 47, 1364-1367.	1.9	20
50	Assessment of long-term anticoagulation in patients with a continuous-flow left-ventricular assist device: A pilot study. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2011, 142, e1-e2.	0.8	69